# Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

> **NCT00255021** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 186 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Poliomyelitis
- Haemophilus Infections
- Pertussis

## Interventions

- **BIOLOGICAL:** Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac

## Key facts

- **NCT ID:** NCT00255021
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-09
- **Final completion:** 2009-01
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255021, "Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00255021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*